THERACRYF PLC - Update on the Ox-1 programme

TheraCryf's Ox-1 orexin-1 blocker cleared toxicology with a wide safety margin, targeting Australian Phase 1 approval by year-end 2025.

• Toxicology package complete: 28-day GLP tox study dosed up to 1g/kg (regulatory maximum, ~70x anticipated human dose) with no adverse histopathological findings, giving a wide safety margin.
• Timeline to clinic: Company targets Australian ethics/TGA submission by mid-November 2025, aiming for approval by year-end to begin first-in-human Phase 1 dosing.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.